Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant plus anastrozole versus anastrozole alone as adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive early breast cancer
2007-003417-14Phase 3Completed
- Sponsor
- GEICAM
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Fulvestrant plus anastrozole with Anastrozole alone (2 arms). Primary endpoint: Disease-free survival. Started Aug 2007; status: completed.
02
Drugs
fulvestrantanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-003417-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003417-14.